Dr. Rita Schmid, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 552
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Indiana University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
IN license 01069108A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hospital of South Bend South Bend, IN
- Lakeland Hospital, St Joseph St Joseph, MI
- Elkhart General Hospital Elkhart, IN
- Saint Joseph Regional Medical Center Mishawaka, IN
- Saint Joseph Regional Medical Center - Plymouth Plymouth, IN
Medical groups
- The South Bend Clinic LLC (175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 552
- Services billed
- 9,203
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 983 | 475 |
| Insertion of needle into vein for collection of blood sample | 964 | 504 |
| Blood test, comprehensive group of blood chemicals | 760 | 475 |
| Blood test, lipids (cholesterol and triglycerides) | 659 | 456 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 656 | 441 |
| Blood test, thyroid stimulating hormone (tsh) | 558 | 426 |
| Hemoglobin a1c level | 419 | 249 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 357 | 357 |
| Manual urinalysis test with examination using microscope, automated | 185 | 166 |
| Vitamin d-3 level | 184 | 163 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $228 in total to this clinician.
| Novo Nordisk Inc | $96.86 |
|---|---|
| Insulet Corporation | $29.20 |
| Amgen Inc. | $28.67 |
| GlaxoSmithKline, LLC. | $22.10 |
| Inspire Medical Systems, Inc. | $20.20 |
| AbbVie Inc. | $16.14 |
| Terumo Medical Corporation | $15.20 |
| Food and Beverage | $228 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $466,514 in research payments for these studies, mostly to the institutions running them.
- A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morb…
AstraZeneca Pharmaceuticals LP - A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
AstraZeneca Pharmaceuticals LP - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A phase 1/2, randomized, observer-blinded, multi-country study to eval
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.